While traditional rapalogs primarily inhibit mTORC1, next-generation mTOR kinase inhibitors and dual PI3K/mTOR compounds—such as gedatolisib—block both mTORC1 and mTORC2 and are in early clinical testing for CRC([118]– [119]). This evidence concerns the gene PIK3CA and colorectal carcinoma.